Study of Psycho- Social Aspects of Schizophrenia at Tertiary Care Hospital in Maharashtra

Ashturkar,; Dixit, Jagannath V; Kulkarni, AP

doi:10.5958/0976-5506.2015.00088.1

Cited by 2 publications

(4 citation statements)

References 0 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…In the present study, the gender distribution and mean age of patients is comparable to that reported in earlier studies. [9][10][11] Demographic characteristics showed that the mean and standard deviation of age of the study patients was (31.267+9.64) years. In an Indian epidemiological study done by Ashturkar et al, in Aurangabad, mean age for the cases was 30.26 years which is comparable to our study.…”

Section: Discussionmentioning

confidence: 99%

“…In an Indian epidemiological study done by Ashturkar et al, in Aurangabad, mean age for the cases was 30.26 years which is comparable to our study. 9 The onset of schizophrenia usually occurs between late teens and the mid-30s. 1 In our study, majority of patients (45.97%) were in the age group of (26-35) years and a higher number of male patients (62%) were observed with male to female ratio of 1:0.61.Similar results were found in a study done by Ashturkar et al, in which it was reported that 66.66% patients were males and 33.33% were females.…”

Section: Discussionmentioning

confidence: 99%

“…1 In our study, majority of patients (45.97%) were in the age group of (26-35) years and a higher number of male patients (62%) were observed with male to female ratio of 1:0.61.Similar results were found in a study done by Ashturkar et al, in which it was reported that 66.66% patients were males and 33.33% were females. 9 McGrath et al studied the incidence and prevalence of schizophrenia and found that the incident was significantly higher in males compared to females; the male/female ratio median was 1:0.4. 10 The onset of schizophrenia is later in women than in men, and the clinical manifestations are less severe.…”

Section: Discussionmentioning

confidence: 99%

See 2 more Smart Citations

A comparative study of effectiveness, safety and cost effectiveness of olanzapine, risperidone and aripiprazole therapy in schizophrenia

Kanani

Pillai

2020

Int J Basic Clin Pharmacol

View full text Add to dashboard Cite

Background: Schizophrenia is the most common psychotic disorder and responsible for approximately half of long-term psychiatric hospitalizations. Antipsychotic medications reduce the psychotic symptoms and prevent relapses. The choice of drug for treatment of schizophrenia depends on many issues, including effectiveness, cost, side-effect burden, availability, and tolerability. Many studies have compared antipsychotic drugs with one another, but no broad consensus has been reached. Our study compares the clinical effectiveness, safety and cost effectiveness of atypical antipsychotics in our setting.Methods: This was an observational, prospective study in which schizophrenia patients receiving either olanzapine, risperidone or aripiprazole were enrolled. Patients were followed up for 3 months. Evaluation of effectiveness was done by analysing mean reduction in PANSS score. Analysis of ADRs was done using WHO causality scale and Hartwig and Siegel severity scale. Cost analysis was done by comparing all three groups in term of cost range of antipsychotic drugs per improvement in PANSS score during the study period.Results: In the present study, the average dose of antipsychotic drugs received by a patient per day was 8.83±2.98 mg in olanzapine group, 4.76±1.12 mg in risperidone group and 20.43±8.5 mg in aripiprazole group. Mean reduction in PANSS score from baseline to 12 weeks was 23.79% in olanzapine group, 25.41% in risperidone group and 24.65% in aripiprazole group. Conclusions: All the groups were equally effective in reduction in PANSS score while risperidone was the most cost effective.

show abstract

Section: Discussionmentioning

confidence: 99%

Section: Discussionmentioning

confidence: 99%

Section: Discussionmentioning

confidence: 99%

See 1 more Smart Citation

A comparative study of effectiveness, safety and cost effectiveness of olanzapine, risperidone and aripiprazole therapy in schizophrenia

Kanani

Pillai

2020

Int J Basic Clin Pharmacol

View full text Add to dashboard Cite

show abstract

“…1,2 World Health Organization (WHO) melaporkan bahwa sekitar 450 juta penduduk mengalami gangguan jiwa paling dominan yaitu skizofrenia. 3,4 Riset Kesehatan Dasar (Riskesdas) Indonesia menyebutkan bahwa prevalensi gangguan jiwa skizofrenia mengalami peningkatan dari tahun 2013 ke 2018 yaitu sebesar 7 per seribu penduduk, dan di Kalimantan Barat pada periode waktu yang sama juga mengalami peningkatan pada tahun 2018 menjadi 8 per seribu penduduk dengan cakupan pengobatan kategori berobat sudah mencapai 84,9% dengan minum obat rutin 48,9%. 5 Terapi yang didapatkan pasien skizofrenia yakni terapi somatik dan psikososial.…”

Section: Pendahuluanunclassified

Comparative Analysis of the Quality of Life of Schizophrenic Patients between Combination Therapy of Risperidone-Haloperidol and Clozapine-Risperidone-Haloperidol in a Mental Health Hospital in West Kalimantan Province

Anggriani¹,

Khairunisa²,

Wilson³

et al. 2022

Indones J Clin Pharm

View full text Add to dashboard Cite

Schizophrenia is one of the most complex mental disorders that can burden individuals and families, and it requires long-term treatment since it is a chronic disease that can potentially relapse. Therefore, this study compared the Health-Related Quality of life (HRQoL) of schizophrenic patients receiving a combination of antipsychotic therapy of risperidone and haloperidol (RH) antipsychotic therapy to clozapine, risperidone, and haloperidol (CRH). This was an observational cohort, prospective, pre-post observation study of schizophrenic inpatients at the Mental Hospital of West Kalimantan Province in the stable and discharge phases. Data were collected prospectively from March–May 2020, and consecutive sampling was conducted on 95 respondents. The Indonesian version of The 5-Level European Quality of Life 5 Dimensions (EQ5D-5L) questionnaire was filled by nurses and patients simultaneously to measure the HRQoL. The pre-therapy analysis performed at the stable phase using the Mann-Whitney test showed no difference in HRQoL between RH and CRH groups (p>0.05). Meanwhile, during the discharge phase (post-therapy), the HRQoL of the RH and CRH groups was not significantly different (p>0.05). The Wilcoxon test showed a significant difference in the RH and CRH groups from the beginning of the patients’ stable phase to the discharge (p<0.05). Therefore, there is a significant difference between RH and CRH combination therapy as well as the HRQoL improvement of schizophrenic patients.

show abstract

Study of Psycho- Social Aspects of Schizophrenia at Tertiary Care Hospital in Maharashtra

Cited by 2 publications

References 0 publications

A comparative study of effectiveness, safety and cost effectiveness of olanzapine, risperidone and aripiprazole therapy in schizophrenia

A comparative study of effectiveness, safety and cost effectiveness of olanzapine, risperidone and aripiprazole therapy in schizophrenia

Comparative Analysis of the Quality of Life of Schizophrenic Patients between Combination Therapy of Risperidone-Haloperidol and Clozapine-Risperidone-Haloperidol in a Mental Health Hospital in West Kalimantan Province

Contact Info

Product

Resources

About